Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Chronic Migraine
Interventions
DRUG

onabotulinumtoxinA

BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).

Trial Locations (1)

65807

Clinvest/A Division of Banyan Group, Inc., Springfield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Cady, Roger, M.D.

INDIV